Evidence map›Paper›PMID 37608128›Full record

ArticleCancer immunology, immunotherapy : CII2023

Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer.

Yakun Zhang, Yue Sun, Jing Gan, Hanxiao Zhou, Shuang Guo, Xinyue Wang, Caiyu Zhang, Wen Zheng, Xiaoxi Zhao, Yunpeng Zhang and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Aging and cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yakun Zhang *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yue Sun *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Jing GanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Hanxiao ZhouCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Shuang GuoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Xinyue WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Caiyu ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Wen ZhengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Xiaoxi ZhaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yunpeng ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. zhangyp@hrbmu.edu.cn.
Shangwei NingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. ningsw@ems.hrbmu.edu.cn.
Xia LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. lixia@hrbmu.edu.cn.
Harbin Medical University · CN

Funding

National Key R&D Program of China 2018YFC2000100National Natural Science Foundation of China 32070672National Natural Science Foundation of China 61873075National Natural Science Foundation of China 62172131
6 · The paper itself

Abstract

Immunosenescence has been demonstrated to play an important role in tumor progression. However, there is lacking comprehensive analyses of immunosenescence-related pathways. Meanwhile, the sex disparities of immunosenescence in cancer are still poorly understood. In this study, we analyzed the multi-omics data of 12,836 tumor samples, including genomics, transcriptomics, epigenomics, proteomics, and metabolomics. We systematically identified immunosenescence pathways that were disordered across cancer types. The mutations and copy number variations of immunosenescence pathways were found to be more active in pan-cancer. We reconstructed the immunosenescence core pathways (ISC-pathways) to improve the ability of prognostic stratification in 33 cancer types. We also found the head and neck squamous carcinoma (HNSC) contained abundant sex-specific immunosenescence features and showed sex differences in survival. We found that OSI-027 was a potential sex-specific drug in HNSC tumors, which tended to be more effective in male HNSC by targeting the MTOR gene in the PI3K-Akt signaling pathway. In conclusion, our study provided a systematic understanding of immunosenescence pathways and revealed the global characteristics of immunosenescence in pan-cancer. We highlighted MTOR gene could be a powerful immunosenescence biomarker of HNSC that helps to develop sex-specific immunosenescence drugs.

Indexed as

Head and Neck NeoplasmsImmunosenescenceDNA Copy Number VariationsFemaleHumansMalePhosphatidylinositol 3-KinasesSquamous Cell Carcinoma of Head and NeckTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesImmunosenescenceMulti-omics analysisPan-cancerPathwaySex difference

Identifiers

PMID37608128
PMCPMC10992234
OpenAlexW4386067085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.